Prognostic effect of programmed cell death ligand 1/programmed cell death 1 expression in cancer stem cells of human oral squamous cell carcinoma

被引:1
|
作者
Todoroki, Keita [1 ,2 ]
Abe, Yushi [1 ,2 ]
Matsuo, Katsuhisa [1 ,2 ]
Nomura, Hidetoshi [1 ]
Kawahara, Akihiko [3 ]
Nakamura, Yoshiaki [4 ]
Nakamura, Moriyoshi [1 ]
Seki, Naoko [1 ]
Kusukawa, Jingo [1 ]
机构
[1] Kurume Univ, Dent & Oral Med Ctr, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan
[2] Kouhoukai Med Corp, Takagi Hosp, Dept Dent & Oral Surg, Okawa, Fukuoka 8310016, Japan
[3] Kurume Univ Hosp, Dept Diagnost Pathol, Kurume, Fukuoka 8300011, Japan
[4] Oita Saiseikai Hita Hosp, Dept Dent & Oral Surg, Hita, Oita 8771292, Japan
关键词
CSC; OSCC; CD44v3; CD24; programmed cell death ligand 1; programmed cell death 1; immune checkpoint inhibitors; HEAD; PD-L1; CD24; IDENTIFICATION; IMMUNOTHERAPY; POPULATION; RECURRENT;
D O I
10.3892/ol.2024.14213
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between cancer stem cells (CSCs) in oral squamous cell carcinoma (OSCC) and programmed cell death ligand 1 (PD-L1)/programmed cell death 1 (PD-1) remains unclear. Therefore, the present study aimed to clarify the association between the CD44v3(high)/CD24(low) immunophenotype of CSCs in OSCC and PD-L1/PD-1 co-expression, and to assess the prognostic effect of CSCs in terms of immune checkpoint molecules. Formalin-fixed, paraffin-embedded tissue samples and clinicopathological data from 168 patients with OSCC were retrospectively retrieved. Immunohistochemical staining and reverse transcription quantitative polymerase chain reaction were applied to a tissue microarray of the invasive front of each case. Semi-automated cell counting was used to assess CD44v3, CD24, PD-L1 and PD-1 expression by immunohistochemistry (IHC) using a digital image analysis program. Associations between immunological markers and clinicopathological variables were estimated. Patients with the CSC immunophenotype CD44v3(high)/CD24(low), and patients with a high PD-L1/PD-1-positive cell density in the tumor parenchyma and stroma had significantly lower survival rates. Furthermore, patients with the CSC immunophenotype (CD44v3(high)/CD24(low)) and high PD-L1/PD-1 co-expression had even lower survival rates (P<0.01, log-rank test). Notably, there was a positive correlation between CD44v3 and PD-L1 expression (tau=0.1096, P=0.0366, Kendall rank correlation coefficient) and a negative correlation between CD24 and PD-1 expression (tau=-0.1387, P=0.0089, Kendall rank correlation coefficient). Additionally, the high CD44v3 expression group, as determined by IHC, exhibited significantly decreased expression of U2 small nuclear RNA auxiliary factor 1 (U2AF1) at the mRNA level compared with that in the low CD44v3 expression group (P<0.001, Mann-Whitney U test), and U2AF1 and PD-L1 mRNA expression exhibited a significant negative correlation (tau=-0.3948, P<0.001, Kendall rank correlation coefficient). In conclusion, CSCs in OSCC may evade host immune mechanisms and maintain CSC stemness via PD-L1/PD-1 co-expression, resulting in unfavorable clinical outcomes.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma
    Villasboas, Jose Caetano
    Ansell, Stephen
    CANCER JOURNAL, 2016, 22 (01) : 17 - 22
  • [22] Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer
    Enkhbat, Tumenjin
    Nishi, Masaaki
    Takasu, Chie
    Yoshikawa, Kozo
    Jun, Higashijima
    Tokunaga, Takuya
    Kashihara, Hideya
    Ishikawa, Daichi
    Shimada, Mitsuo
    ANTICANCER RESEARCH, 2018, 38 (06) : 3367 - 3373
  • [23] Expression of programmed cell death protein 1 and programmed cell death ligand 1 in feline injection site fibrosarcomas
    Mikiewicz, Mateusz
    Pazdzior-Czapula, Katarzyna
    Fiedorowicz, Joanna
    Otrocka-Domaga, Iwona
    RESEARCH IN VETERINARY SCIENCE, 2024, 176
  • [24] Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma
    Yokoyama, Shintaro
    Miyoshi, Hiroaki
    Nakashima, Kazutaka
    Shimono, Joji
    Hashiguchi, Toshihiro
    Mitsuoka, Masahiro
    Takamori, Shinzo
    Akagi, Yoshito
    Ohshima, Koichi
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4727 - 4734
  • [25] Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 Is a Prognostic Factor for Malignant Melanoma
    Hino, Ryosuke
    Kabashima, Kenji
    Kato, Yu
    Yagi, Hiroaki
    Nakamura, Motonobu
    Honjo, Tasuku
    Okazaki, Taku
    Tokura, Yoshiki
    CANCER, 2010, 116 (07) : 1757 - 1766
  • [26] Clinical Significance of Programmed Death Ligand-1 Expression in Esophageal Squamous Cell Carcinoma
    Ito, Nozomi
    Tsujimoto, Hironori
    Horiguchi, Hiroyuki
    Shimazaki, Hideyuki
    Miyazaki, Hiromi
    Saitoh, Daizoh
    Kishi, Yoji
    Ueno, Hideki
    JOURNAL OF SURGICAL RESEARCH, 2020, 251 : 321 - 328
  • [27] Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
    Pezeshki, Parmida Sadat
    Mahdavi Sharif, Pouya
    Rezaei, Nima
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (12) : 1575 - 1590
  • [28] Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
    Droeser, Raoul A.
    Hirt, Christian
    Viehl, Carsten T.
    Frey, Daniel M.
    Nebiker, Christian
    Huber, Xaver
    Zlobec, Inti
    Eppenberger-Castori, Serenella
    Tzankov, Alexander
    Rosso, Raffaele
    Zuber, Markus
    Muraro, Manuele Giuseppe
    Amicarella, Francesca
    Cremonesi, Eleonora
    Heberer, Michael
    Iezzi, Giandomenica
    Lugli, Alessandro
    Terracciano, Luigi
    Sconocchia, Giuseppe
    Oertli, Daniel
    Spagnoli, Giulio C.
    Tornillo, Luigi
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (09) : 2233 - 2242
  • [29] The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung
    Igarashi, Tomoyuki
    Teramoto, Koji
    Ishida, Mitsuaki
    Hanaoka, Jun
    Daigo, Yataro
    ONCOLOGY REPORTS, 2017, 38 (04) : 2189 - 2196
  • [30] Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas
    Kwon, Dohee
    Kim, Sehui
    Kim, Pil-Jong
    Go, Heounjeong
    Nam, Soo Jeong
    Paik, Jin Ho
    Kim, Young A.
    Kim, Tae Min
    Heo, Dae Seog
    Kim, Chul Woo
    Jeon, Yoon Kyung
    HISTOPATHOLOGY, 2016, 68 (07) : 1079 - 1089